Search Results for "CT P6 Celltrion"

15:40 EDT 4th October 2015 | BioPortfolio

Matching Channels


Matching News

Celltrion, Inc. - Product Pipeline Review - 2015

Celltrion, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2015’, provides an overview of the Celltrion, Inc.’s pharmaceutic...

Celltrion Healthcare Aims For IPO After FDA Green Lights Remsima

With Celltrion still awaiting the U.S. FDA's approval of its proposed biosimilar of Remicade (infliximab), its marketing subsidiary Celltrion Healthcare is aiming to launch a planned initial public of...

Hospira/Celltrion: Don't Let U.S. Biosimilar Law's Questions 'Percolate'

"Further percolation will not advance the law," Hospira and Celltrion said, insisting that "settling the issue will spur competition."

Celltrion expects to receive FDA nod for Remicade biosimilar this year

Celltrion announced that it plans to market Remsima, a biosimilar version of Johnson & Johnson's and Merck & Co.'s rheumatoid -More- 

Korea's Celltrion Sets Sights on U.S. Market

Celltrion, which sells a cheap version of a top-selling rheumatoid arthritis drug in Europe, is now targeting the U.S., the world’s biggest pharmaceutical market.

Remsima's US FDA review held back by contradictory demands, says Celltrion

Contradictory requests from the US FDA on the statistical analysis of Remsima are one of many regulatory hurdles facing biosimilar developers, according to Celltrion.

Celltrion presents data at US conference

Celltrion’s Remsima campaign rolled into the US this week with another presentation of data showing that the Remicade (Infliximab) biosimilar is equivalent to the reference drug.

Celltrion presents data showing clinical benefit of its biosimilar infliximab

Korean biopharma company Celltrion Healthcare has presented data on the clinical experience of patients…

Matching PubMed Articles


Search Whole site using Google


Advertisement Advertisement